Abstract 1065
Background
Köhne prognostic category classifies mCRC pts as high, medium or low risk. Retrospective analysis of phase 3 trials found that Köhne category predicts survival, pts with BRAF mutant (MT) mCRC represent a separate (higher risk) category, and Pmab-based therapy improves survival vs chemotherapy alone in all four risk groups. We evaluated whether higher Köhne category and BRAF status predicts worse ETS and DpR, and assessed outcomes by ETS ≥30% vs < 30% and DpR category.
Methods
Retrospective analysis of RAS WT mCRC pts from the phase 3 PRIME study. ETS (% reduction in the sum of the longest diameters of measurable lesions at week 8) and DpR (maximum % change from baseline to nadir [shrinkage]; % change at progressive disease [no shrinkage]) were analysed according to Köhne category. DpR groups: <0%; 0–30%; 31–52%; 53–70%; 71–100%. BRAF MT pts were considered separately. Treatment arms were pooled and analysed separately.
Results
436 pts receiving treatment (FOLFOX±Pmab) were analysed for ETS, 456 for DpR. The % pts in low-, medium-, high-risk and BRAF MT groups, respectively, achieving ETS ≥30% was 63.8%, 50.4%, 41.9% and 21.7%, and DpR 71–100% was 47.7%, 23.6%, 10.0% and 4.2%. Pts with ETS ≥30% vs < 30% achieved longer PFS and OS, irrespective of Köhne category; this effect was not seen in BRAF MT pts (Table). In all Köhne groups, deeper DpR was generally associated with longer PFS and OS; this trend was noted in the BRAF MT group, but to a lesser extent. For all analyses, similar trends were seen in individual treatment arms (data not shown).Table:
572P Median PFS and OS by ETS ≥30% vs < 30% and by DpR category for each Köhne prognostic category and in pts with BRAF MT mCRC. P+F=Pmab+FOLFOX, F=FOLFOX alone
ETS1,2 | High (n = 74) | Medium (n = 236) | Low (n = 80) | BRAF MT (n = 46) |
---|---|---|---|---|
Median PFS, months | ||||
≥30% | 13.9 | 12.8 | 15.4 | 5.6 |
<30% | 6.1 | 8.9 | 9.2 | 5.8 |
Median OS, months | ||||
≥30% | 24.6 | 32.5 | 40.7 | 9.6 |
<30% | 11.7 | 19.3 | 23.6 | 10.4 |
DpR3 | High (n = 80) | Medium (n = 242) | Low (n = 86) | BRAF MT (n = 48) |
Median PFS, months | ||||
<0% | 2.4 | 2.0 | 4.0 | 2.1 |
0–30% | 5.0 | 5.4 | 5.4 | 6.0 |
31–52% | 10.2 | 10.6 | 8.5 | 5.6 |
53–70% | 13.7 | 11.5 | 9.9 | 14.9 |
71–100% | 22.4 | 17.3 | 17.7 | 10.4 |
Median OS, months | ||||
<0% | 5.5 | 7.5 | 10.7 | 6.4 |
0–30% | 9.4 | 14.3 | 13.6 | 10.9 |
31–52% | 13.8 | 23.6 | 20.0 | 9.4 |
53–70% | 23.1 | 30.9 | 28.4 | 39.5 |
71–100% | 33.2 | 62.1 | 47.4 | 21.4 |
Number of patients evaluable for ETS and DpR differ as patients with disease progression or death before week 8 did not have ETS data available;.
2For ETS ≥30%: n = 128 (P+F), n = 83 (F); ETS <30%: n = 88 (P+F), n = 137 (F);.
3For DpR <0%: n = 17 (P+F), n = 26 (F); 0–30%: n = 42 (P+F), n = 47 (F); 31–52%: n = 52 (P+F), n = 54 (F); 53–70%: n = 57 (P+F), n = 53 (F); 71–100%: n = 65 (P+F), n = 43 (F).
Conclusions
Higher-risk categories predict worse ETS and DpR in pts with RAS WT mCRC. Irrespective of risk category, pts achieving ETS ≥30% vs < 30% survived longer. Although patient numbers were small, prognosis in BRAF MT group was poor irrespective of ETS, but OS/PFS were longer with deeper DpR.
Clinical trial identification
NCT00364013.
Editorial acknowledgement
David Cutler, PhD, CMPP of Aspire Scientific (Bollington, UK) and funded by Amgen (Europe) GmbH (Rotkreuz, Switzerland).
Legal entity responsible for the study
Amgen (Europe) GmbH.
Funding
Amgen (Europe) GmbH.
Disclosure
A. Sartore-Bianchi: Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: Sanofi. M. Peeters: Honoraria (self), Research grant / Funding (self), Research grant / Funding (institution): Amgen; Honoraria (self), Research grant / Funding (self), Research grant / Funding (institution): Roche; Honoraria (self): Lilly; Honoraria (self): Merck Serono; Honoraria (self): Remedus; Honoraria (self): Sanofi-Aventis; Honoraria (self): Servier; Honoraria (self): Sirtex; Honoraria (self): Terumo. M. Geissler: Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Amgen; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Sanofi. J. Taieb: Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self), Advisory / Consultancy: Celgene; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Sanofi; Honoraria (self), Advisory / Consultancy: Servier; Honoraria (self), Advisory / Consultancy: Sirtex. P. García-Alfonso: Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Sanofi; Honoraria (self), Advisory / Consultancy: Servier. T. Price: Advisory / Consultancy, Travel / Accommodation / Expenses: Amgen; Advisory / Consultancy: Merck Serono; Advisory / Consultancy: Roche. P. Burdon: Shareholder / Stockholder / Stock options, Full / Part-time employment: Amgen (Europe) GmbH. Y. Zhang: Shareholder / Stockholder / Stock options, Full / Part-time employment: Amgen Inc. C. Koehne: Honoraria (self): Amgen; Honoraria (self): Bayer; Honoraria (self): Merck; Honoraria (self): Pfizer; Honoraria (self): Servier.
Resources from the same session
2551 - Efficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: an exploratory analysis of the GIM2 trial.
Presenter: Benedetta Conte
Session: Poster Display session 2
Resources:
Abstract
3426 - High dose Neo-adjuvant chemotherapy in Triple-Negative breast cancer with evidence of homologous recombination deficiency (HRD).
Presenter: Sonja Vliek
Session: Poster Display session 2
Resources:
Abstract
3792 - Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: pooled analysis of prospective neoadjuvant breast cancer (BC) trials
Presenter: Gustavo Werutsky
Session: Poster Display session 2
Resources:
Abstract
4044 - Estimating radiotherapy-induced cardiovascular mortality in female breast cancer patients.
Presenter: Mark De Ridder
Session: Poster Display session 2
Resources:
Abstract
719 - 3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)
Presenter: Justin Stebbing
Session: Poster Display session 2
Resources:
Abstract
3595 - Adjuvant chemotherapy in elderly breast cancer patients: pattern of use and impact on overall survival
Presenter: Axel Berthelot
Session: Poster Display session 2
Resources:
Abstract
3992 - Carboplatin-containing neoadjuvant chemotherapy for triple negative breast cancer (TNBC): a propensity score-matched study.
Presenter: Maria Vittoria Dieci
Session: Poster Display session 2
Resources:
Abstract
3477 - Impact of adjuvant trastuzumab emtansine (T-DM1) on incidence of metastatic breast cancer (mBC): an epidemiological model of patients with HER2-positive breast cancer (BC) who did not achieve pathological complete response (pCR) after neoadjuvant treatment (non-pCR)
Presenter: Mellissa Williamson
Session: Poster Display session 2
Resources:
Abstract
3928 - Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study
Presenter: Hans Tesch
Session: Poster Display session 2
Resources:
Abstract
2184 - The clinical impact of adjuvant dose-dense sequential chemotherapy (dds-CT) in patients with high-risk operable breast cancer (BC); pooled analysis of 6 clinical trials.
Presenter: Elena Fountzilas
Session: Poster Display session 2
Resources:
Abstract